As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.
13 Analysts have issued a Clene Inc forecast:
13 Analysts have issued a Clene Inc forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 0.21 0.21 |
50%
50%
|
|
| Gross Profit | 0.18 0.18 |
45%
45%
|
|
| EBITDA | -23 -23 |
30%
30%
|
|
| EBIT (Operating Income) EBIT | -24 -24 |
29%
29%
|
|
| Net Profit | -31 -31 |
15%
15%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutics for neurodegenerative diseases. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded on August 12, 2020 and is headquartered in Salt Lake City, UT.
| Head office | United States |
| CEO | Robert Etherington |
| Employees | 76 |
| Founded | 2013 |
| Website | clene.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


